digital therapeutics

By Dave Muoio June 12, 2019
Yesterday, CVS Health unveiled Vendor Benefit Management, a new service that will help CVS Caremark pharmacy benefit management (PBM) clients roll out and manage third-party health products. As the service is applicable to both digital and non-digital health and wellness products, the company has decided to inaugurate its initiative by announcing Big Health — maker of the CBT-based sleep app...
By Dave Muoio June 5, 2019
Healthcare is in the midst of a digital shift. Artificial intelligence offers physicians providers an new resource when making decisions, new data streams promise hyper-personalized treatments and digital therapeutics evangelists see are hawking the novel treatments as a companion, or even a replacement, to traditional biologic treatments. All in all, it’s a future that hopes to empower the...
By Dave Muoio May 16, 2019
Express Scripts will be releasing a stand-alone formulary in 2020 that highlights vetted digital health tools for the pharmacy benefit management firm’s payer and consumer customers, according to an announcement released this morning. The company said that it will be treating the new formulary in much the same way it would a similar resource for traditional medications. To be included, a digital...
By Joe Slavinsky May 16, 2019
About the author: Joe Slavinsky leads business development efforts with pharmaceutical, biotechnology and medical technology companies in his VP position at Propeller Health. A former epidemiologist, he worked at a hedge fund (Citadel) and an investment bank (Thomas Weisel Partners) as an equity research analyst covering small/mid-cap biotechnology companies. Joe joined Propeller from Gilead...
By Leontina Postelnicu May 9, 2019
Health tech startup Closed Loop Medicine has raised £2.1m in a pre-Series A funding round from Longwall Venture Partners, IQ Capital and Martlet, it was announced this morning. The Cambridge startup, which describes itself as a "new breed of therapeutics company", says its approach is based on using data and insights about how patients are responding to treatments to tailor drug and non-drug...
By Dave Muoio May 6, 2019
Editor's Note: An original headline for this story contained an error, and has since been corrected. Boston- and San Francisco-based Pear Therapeutics, maker of prescription digital therapeutics for substance abuse, has kicked off a feasibility study for Pear-006, an in-development treatment for depressive symptoms in those with multiple sclerosis (MS). Pear Therapeutics has been developing Pear-...

Screengrab of QTC Care's website.

By Dean Koh April 29, 2019
Established in the US in 2013, Shanghai-headquartered QTC Care, a healthcare platform that uses AI to streamline treatment recovery and disease prevention, announced that it has raised $7M in series A funding. The investment was led by a Chinese internet giant, Tencent, followed by several other top investors in China. Just last week, Tencent-backed Trusted Doctor said that it had raised $250M in...
By Laura Lovett April 11, 2019
There is an app for just about everything, and the mental health space is no different. But industry experts warn that not all mental health apps are created equally. While there are exemplars of tools that have been clinically validated, there is also a slew of technologies that have not been tested at all.  “There are lot of opportunities for patients to receive bad care through apps right now...
By Dave Muoio April 10, 2019
A study published last month in JMIR Cardio demonstrated significant systolic and diastolic blood pressure reductions in hypertension patients who received a mobile app-based behavior change intervention. The investigation examined Better Therapeutics’ candidate digital therapeutic for cardiovascular disease, a daily-use app that encourages users to set and record their progress toward...
By Dave Muoio April 9, 2019
Although still in its earliest chapters, the story of digital thherapeutics is beginning to pick up steam. Just six months ago, that the first software-only therapeutic cleared by the FDA, Pear Therapeutics’ reSET, kicked off a commercial launch driven by the sales channels expertise of an established pharmaceutical partner. Proteus, meanwhile, recently expanded dealings with its long-time pharma...